- Glaukos Announces First Quarter 2024 Financial Results
- Glaukos Announces the Release of its 2023 Sustainability Report
- Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
- Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
- Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
More ▼
Key statistics
As of last trade Glaukos Corp (GKOS:NYQ) traded at 108.73, -4.60% below its 52-week high of 113.97, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 108.09 |
---|---|
High | 109.62 |
Low | 107.28 |
Bid | 108.48 |
Offer | 108.97 |
Previous close | 107.44 |
Average volume | 391.64k |
---|---|
Shares outstanding | 50.37m |
Free float | 48.62m |
P/E (TTM) | -- |
Market cap | 5.41bn USD |
EPS (TTM) | -2.88 USD |
Data delayed at least 15 minutes, as of May 24 2024 18:06 BST.
More ▼